Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
Authors
Keywords
Prognosis, Epithelial ovarian cancer (EOC), Topoisomerases, Kaplan Meier plotter, Oncomine
Journal
Journal of Ovarian Research
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-06-18
DOI
10.1186/s13048-016-0244-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SSBP1 Suppresses TGF -Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling
- (2015) H.-L. Jiang et al. CANCER RESEARCH
- TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin
- (2015) J. Erriquez et al. GYNECOLOGIC ONCOLOGY
- Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma
- (2015) Claire Bonneau et al. GYNECOLOGIC ONCOLOGY
- Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling
- (2015) Hong-Lin Jiang et al. Oncotarget
- Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells
- (2014) Jian-wei Zhang et al. BIOCHEMICAL PHARMACOLOGY
- DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression
- (2014) M.-Y. Hsieh et al. CLINICAL CANCER RESEARCH
- A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development
- (2014) Cheryl A Sherman-Baust et al. JOURNAL OF PATHOLOGY
- Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to Irinotecan
- (2014) C. Meisenberg et al. MOLECULAR CANCER THERAPEUTICS
- Arginine Methylation Facilitates the Recruitment of TOP3B to Chromatin to Prevent R Loop Accumulation
- (2014) Yanzhong Yang et al. MOLECULAR CELL
- Topoisomerase IIα in chromosome instability and personalized cancer therapy
- (2014) T Chen et al. ONCOGENE
- Topoisomerase I as a Biomarker: Detection of Activity at the Single Molecule Level
- (2014) Joanna Proszek et al. SENSORS
- A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer
- (2013) Zsuzsanna Mihály et al. BREAST CANCER RESEARCH AND TREATMENT
- Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity
- (2013) P Vejpongsa et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Role of Replication Protein A in Double Holliday Junction Dissolution Mediated by the BLM-Topo IIIα-RMI1-RMI2 Protein Complex
- (2013) Xiaoyu Xue et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- (2013) Balázs Győrffy et al. PLoS One
- Co-evolution of Human Leukocyte Antigen (HLA) Class I Ligands with Killer-Cell Immunoglobulin-Like Receptors (KIR) in a Genetically Diverse Population of Sub-Saharan Africans
- (2013) Paul J. Norman et al. PLoS Genetics
- Optimal first-line treatment in ovarian cancer
- (2012) F. A. Raja et al. ANNALS OF ONCOLOGY
- High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
- (2012) J H Song et al. BRITISH JOURNAL OF CANCER
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
- (2012) Balázs Győrffy et al. ENDOCRINE-RELATED CANCER
- Topoisomerase 1(TOP1 ) gene copy number in stage III colorectal cancer patients and its relation to prognosis
- (2012) Maria Unni Rømer et al. Molecular Oncology
- The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
- (2012) Dan-Dan Li et al. PLoS One
- Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan
- (2010) S. A.L. Zander et al. CANCER RESEARCH
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
- (2010) Yves Pommier et al. CHEMISTRY & BIOLOGY
- Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines
- (2010) Chandra M. Das et al. EUROPEAN JOURNAL OF CANCER
- Significance of topoisomerase IIIβ expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis
- (2010) João Paulo Oliveira-Costa et al. HUMAN PATHOLOGY
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
- (2010) Kae Hashimoto et al. MOLECULAR CANCER THERAPEUTICS
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis
- (2009) Areeg Faggad et al. MODERN PATHOLOGY
- Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
- (2008) G Ferrandina et al. BRITISH JOURNAL OF CANCER
- Defective p53 engagement after the induction of DNA damage in cells deficient in topoisomerase 3β
- (2008) Subhasis Mohanty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNA topoisomerases: harnessing and constraining energy to govern chromosome topology
- (2008) Allyn J. Schoeffler et al. QUARTERLY REVIEWS OF BIOPHYSICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started